Oxycodone: Nursing Drug Guide, Respiratory Depression & Hold Rules
Oxycodone can cause fatal respiratory depression—especially during the first 24–72 hours after initiation or a dose increase, when benzodiazepines or other CNS depressants stack, or when immediate-release and extended-release products are confused. Nurses must confirm formulation on the MAR, never crush extended-release tablets, and assess ventilation before every dose.
Oxycodone hydrochloride can cause serious, life-threatening, or fatal respiratory depression, especially during initiation or after a dose increase. Labeling instructs close monitoring—particularly within the first 24 to 72 hours of starting therapy or raising the dose. Concomitant benzodiazepines, other CNS depressants, or alcohol may cause profound sedation, coma, and death. Extended-release tablets must be swallowed whole; crushing or chewing can release a potentially fatal dose. Overestimating dose when converting from another opioid can cause fatal overdose with the first dose. Discuss naloxone access per labeling; assess respiratory rate, sedation, and oxygenation before every dose.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every oxycodone dose, assess respiratory rate, oxygen saturation, and arousability—and confirm immediate-release versus extended-release on the MAR. Count cumulative opioid and sedative doses in 24 hours. An acceptable pain score never overrides inadequate ventilation.
Most common brand names
Oxycodone is available as immediate-release tablets, extended-release tablets (e.g., OxyContin), and combination products with acetaminophen or aspirin. Always verify the specific formulation and release mechanism on the MAR—not just the word “oxycodone.”
Common names include Roxicodone and generic oxycodone hydrochloride immediate-release tablets (5, 10, 15, 20, and 30 mg per reviewed labeling), OxyContin (extended-release), and Oxaydo. Combination brands such as Percocet (oxycodone with acetaminophen) add hepatotoxicity risk from cumulative acetaminophen—verify both components on the MAR.
Why we give it — Indications
Oxycodone hydrochloride is an opioid agonist indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Nurses encounter oxycodone after surgery, injury, and cancer-related pain on medical-surgical floors and outpatient settings where respiratory status and sedative co-therapy must be tracked across shifts.
| Use | Detail |
|---|---|
| Moderate to severe pain | Management of pain severe enough to require an opioid analgesic when non-opioid options are insufficient—many acute pain episodes require only a few days of opioid therapy per labeling. |
| Limitations of use | Reserve oxycodone for patients in whom lower doses are insufficient and expected benefits clearly outweigh substantial risks of addiction, abuse, misuse, and respiratory depression. Use the lowest effective dose for the shortest duration consistent with treatment goals. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Oxycodone binds mu-opioid receptors in the central nervous system, producing analgesia and dose-related respiratory depression by reducing brain-stem responsiveness to carbon dioxide. Carbon dioxide retention from opioid-induced respiratory depression can further increase sedation—a reinforcing risk spiral nurses must recognize early. Concurrent benzodiazepines, sedative-hypnotics, alcohol, and other opioids synergistically increase fatal respiratory depression per boxed warning. CYP3A4 inhibitors can raise oxycodone plasma levels and prolong adverse effects, including potentially fatal respiratory depression.
Dosing overview
Dosing must be individualized and titrated to effect with continuous respiratory monitoring. The grid below reflects reviewed oxycodone hydrochloride immediate-release tablet labeling; extended-release products (e.g., OxyContin) have separate prescribing information—never substitute formulations without prescriber and pharmacy review.
Missed dose: Not specified in the reviewed immediate-release tablet labeling for scheduled regimens. For PRN orders, do not double doses; reassess pain and respiratory status before the next dose and verify cumulative opioid exposure in the last 24 hours.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Elimination half-life (IR tablets) | Approximately 3.5 to 4 hours after oxycodone hydrochloride tablet administration per reviewed labeling | Overlapping PRN doses can stack sedation—count total milligrams in 24 hours |
| High-risk monitoring window | Greatest respiratory depression risk during initiation or after dosage increase; monitor closely especially first 24–72 hours per labeling | Increase respiratory assessments during titration; do not leave high-risk patients unattended after dose changes |
| Onset / peak (oral IR) | Not specified in the reviewed tablet labeling nursing summary | Reassess sedation and respiratory rate on a schedule matched to PRN frequency (every 4–6 hours when used as labeled) |
| Metabolism | Hepatic via CYP3A4 and CYP2D6; renal excretion of oxycodone and metabolites per labeling | CYP3A4 inhibitors increase oxycodone levels—coordinate with pharmacy when new interacting drugs are added |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Discuss and assess patient access to naloxone when initiating or renewing therapy per labeling, especially with CNS depressant co-therapy
- Review baseline respiratory status, COPD, sleep apnea, renal function, and concurrent CNS depressants on the MAR
- Perform medication reconciliation for cumulative opioid and sedative exposure; verify tablet strength (mg), immediate-release versus extended-release, and scheduled versus PRN orders
- Screen for MAOI use within the last 14 days; confirm no known or suspected gastrointestinal obstruction
Contraindications
- Significant respiratory depression
- Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
- Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within 14 days of stopping treatment (MAOI interaction noted in reviewed labeling drug-interactions section)
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Hypersensitivity to oxycodone (e.g., anaphylaxis)
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Benzodiazepines and other CNS depressants | Profound sedation, respiratory depression, coma, and death per boxed warning | Reserve concomitant use only when alternatives are inadequate; use lowest doses and shortest duration; hold oxycodone if excessive sedation or bradypnea develops |
| CYP3A4 inhibitors (e.g., macrolide antibiotics, azole antifungals, protease inhibitors) | May increase oxycodone plasma concentration and prolong opioid adverse reactions, including potentially fatal respiratory depression | Evaluate patients at frequent intervals when inhibitors are added or inducers stopped; consider dosage reduction per prescriber/pharmacist |
| MAOIs | Labeling drug-interactions section notes MAOIs may potentiate opioid effects | Avoid concomitant use in patients receiving MAOIs or within 14 days of stopping an MAOI unless prescriber directs otherwise |
| Mixed agonist-antagonists (e.g., buprenorphine) | May reduce analgesia or precipitate withdrawal; respiratory effects unpredictable | Coordinate with prescriber/pharmacy before co-administration; monitor ventilation |
| Other opioids | Additive respiratory depression and sedation | Calculate total opioid equivalents in 24 hours; clarify orders before stacking agents |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Reviewed oxycodone hydrochloride tablets are for oral administration. Oxycodone is a Schedule II controlled substance—follow institutional controlled-substance policies and high-alert medication administration workflows.
- Confirm immediate-release versus extended-release product; swallow extended-release tablets whole—do not crush, chew, or dissolve per OxyContin and ER labeling
- Independent double-check tablet strength (mg) against the MAR; verify patient can swallow safely
- Do not interchange IR and ER oxycodone or combination products (e.g., Percocet) without prescriber and pharmacy review
- Document time, dose (mg), formulation, route, indication, pre- and post-administration respiratory assessment, and double-check participants
Labeling warns that overestimating oxycodone dose when converting from another opioid can cause fatal overdose with the first dose. Crushing or chewing extended-release oxycodone can release a potentially fatal dose. Accidental ingestion of even one dose—especially by children—can cause respiratory depression and death.
Expected therapeutic response
- Decrease in pain score on standardized pain assessment without excessive sedation
- Respiratory rate and depth remain within prescriber or protocol parameters; patient remains easily arousable
- SpO2 stable on baseline oxygen therapy; no new bradypnea or shallow breathing pattern
Red flags — Stop and act
Respiratory depression may progress from subtle sedation to apnea—especially during the first 24–72 hours after initiation or a dose increase, or when benzodiazepines and opioids stack on the MAR. Escalate immediately.
- Respiratory rate below institutional threshold, shallow respirations, or absent effort (apnea)
- SpO2 decline or new difficulty breathing despite supplemental oxygen
- Marked excessive sleepiness, inability to arouse, or confusion with somnolence
- Severe hypotension, bradycardia, or circulatory depression (labeling lists serious cardiovascular adverse reactions)
- Any suspicion of opioid overdose—initiate airway support and antagonist protocol per facility policy
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Respiratory depression, apnea | Most serious; may be fatal | Stop opioid, support airway, administer antagonist per protocol, continuous monitoring until spontaneous respiration reliably re-established |
| Nausea, constipation, vomiting, headache | Most common adverse reactions (≥ 3%) per reviewed labeling | Proactive bowel regimen; antiemetic per order; monitor hydration |
| Pruritus, dizziness, somnolence, insomnia, asthenia | Listed among common reactions (≥ 3%) | Monitor sedation scale and RR; hold additional doses if oversedated |
| Constipation | Common opioid effect | Proactive bowel regimen per protocol; teach prevention |
| Hypotension, circulatory depression | Serious when reported | Monitor hemodynamics; avoid in circulatory shock per labeling |
| Hypersensitivity / anaphylaxis | Listed in contraindications and adverse reactions | Stop permanently; treat per severe allergy protocol if present |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Overdose manifests primarily as respiratory depression ranging from reduced rate to apnea. Circulatory depression, respiratory arrest, shock, and cardiac arrest are also listed among the most serious adverse reactions in reviewed labeling.
Early signs
- Increasing sedation, miosis, declining respiratory rate or depth
- Hypoxemia on pulse oximetry despite supplemental oxygen
- Carbon dioxide retention worsening sedation (narcotic effect per labeling)
Antidote
Opioid antagonists such as naloxone are specific antidotes to respiratory depression resulting from opioid overdose per reviewed prescribing information. For clinically significant respiratory or circulatory depression, administer an opioid antagonist while supporting ventilation. Continue monitoring and repeat antagonist doses as directed because reversal duration may be shorter than oxycodone action—especially in physically dependent patients, where titrated reversal avoids precipitated withdrawal while restoring ventilation.
Contact local poison control or medical toxicology services for overdose guidance per facility protocol and local emergency guidance. Maintain airway and ventilation while awaiting specialist input.
Look-alike / sound-alike and error prevention
- Oxycodone vs hydrocodone—similar names and oral tablet appearances; verify generic name and strength on bottle and MAR
- OxyContin vs MS Contin—both are extended-release opioids with different active ingredients; read brand and generic names independently
- Oxycodone vs oxymorphone—different potency; confirm generic name before administration
- 5 mg vs 10 mg vs 30 mg tablets—independent double-check tablet strength before every dose
- IR vs ER vs combination (Percocet)—never substitute formulations without prescriber and pharmacy review
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| First 24–72 hours | Labeling directs close monitoring especially when initiating therapy or increasing dose—respiratory depression risk is greatest in this window. |
| ER tablet safety | Teach patients not to crush, chew, or dissolve OxyContin or other extended-release oxycodone; store securely away from children. |
| Bowel regimen | Start prophylactic constipation measures with ongoing opioid therapy unless contraindicated. |
| CYP3A4 inhibitors | New macrolide, azole antifungal, or protease inhibitor on MAR may raise oxycodone levels—notify pharmacy before next dose. |
| Commonly missed | Scheduled benzodiazepine on MAR plus PRN oxycodone without reassessment of cumulative sedation and respiratory rate. |
| Ask pharmacy when | Opioid rotation or conversion, IR versus ER mismatch, partial antagonist response, or recurrent depression after naloxone. |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Elderly, cachectic, debilitated | Life-threatening respiratory depression more likely because of altered pharmacokinetics or clearance—start at low end of dosing range and monitor closely per labeling. |
| COPD, cor pulmonale, decreased respiratory reserve | Even recommended doses may decrease respiratory drive including apnea—continuous SpO2 monitoring and lower starting doses. |
| Concurrent CNS depressants | Reserve concomitant benzodiazepines or sedatives only when alternatives inadequate; profound respiratory depression risk. |
| Pregnancy / labor | Extended opioid use during pregnancy can cause neonatal opioid withdrawal syndrome; oxycodone hydrochloride is not recommended during or immediately prior to labor when other analgesic techniques are more appropriate per labeling. |
| Breastfeeding | Oxycodone is present in breast milk; reviewed labeling states doses less than 60 mg/day of immediate-release oxycodone are unlikely to cause clinically relevant infant exposure, but monitor infants for sedation and respiratory depression—coordinate with prescriber when concern exists. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Respiratory rate, depth, and pattern; sedation level; blood pressure and heart rate per protocol
- Continuous or frequent pulse oximetry during titration and for at least 24–72 hours after initiation or dose increase when policy requires
- Pain scores alongside ventilation—analgesia without adequate respiration is not a safe outcome
- Bowel function, urine output, and mental status on ongoing therapy
Document
- Dose (mg), formulation (IR vs ER), route, time, indication, pre/post respiratory assessment, and independent double-check
- Cumulative opioid and sedative exposure at handoff; antagonist doses and response if given
- Patient education on reporting somnolence, breathing difficulty, and constipation
Patient teaching
- Oxycodone can slow breathing to a dangerous level—report unusual sleepiness, slow or shallow breathing, or difficulty staying awake; seek emergency help per local guidance if overdose is suspected even after naloxone is given
- Do not take other sedatives, alcohol, or extra pain medicine unless the prescriber approves—combined drugs increase overdose risk
- Prevent constipation with fluids, fiber, and prescribed laxatives as directed
- Seek urgent help for severe breathing difficulty or inability to arouse; contact local poison control or toxicology services per facility protocol for overdose guidance
- If breastfeeding, report infant limpness, poor feeding, or unusual sleepiness to the care team immediately
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Significant respiratory depression, apnea, or SpO2 below protocol threshold
- Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment
- Known or suspected gastrointestinal obstruction, MAOI use within 14 days, or hypersensitivity to oxycodone
- Excessive sedation or patient unarousable
- Wrong tablet strength, immediate-release given when extended-release was ordered (or vice versa), or independent double-check mismatch
- New concurrent CNS depressant without a revised safe opioid plan
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Oxycodone is one of the most frequently prescribed oral opioids, but its primary nursing failure mode is treating pain scores while missing declining ventilation—especially when sedatives stack on the MAR or when extended-release tablets are crushed or duplicated with immediate-release doses. Build respiratory assessment into every opioid pass and shift handoff.
1. Check-before-you-give protocol
- Right patient, right drug, right mg strength, right formulation (IR vs ER), right route, right time
- Independent double-check with second licensed clinician per high-alert policy for opioid administration
- Confirm naloxone access, airway equipment, and trained responder availability per unit protocol
- Baseline RR, SpO2, and sedation score documented before dose and per protocol after—especially during the first 24–72 hours after initiation or dose increase
2. High-alert and safety badge
Schedule II high-alert opioid — IR/ER formulation riskLabeling requires discussion of naloxone access when initiating or renewing therapy and warns that overestimating dose on opioid conversion or crushing extended-release tablets can cause fatal overdose.
3. Clinical workflow: hold and question rules
- If RR is declining or SpO2 falling after a dose, hold further oxycodone and escalate before repeating analgesia
- Handoff must include last oxycodone dose, concurrent sedatives, concentration used, and whether ventilation is stable
- Contact poison control or toxicology per facility protocol when overdose is suspected; maintain airway while awaiting guidance
4. Critical teach-back questions
- “What breathing changes should you report right away while receiving oxycodone?” (Patient should name slow or shallow breathing, extreme sleepiness, or difficulty waking up.)
- “Why should you avoid extra sedatives or alcohol with oxycodone?” (Patient should understand combined drugs can stop breathing.)
5. Care coordination
Pharmacist: Consult for IR/ER verification, opioid conversion, CYP3A4 interactions, and antagonist dosing when partial or recurrent reversal occurs
Prescriber: Notify for persistent respiratory depression, need for alternate analgesia, neonatal exposure concerns, or repeated naloxone doses
🧠 Quick mental checklist
- What is this patient’s respiratory rate, depth, SpO2, and arousability right now?
- What oxycodone and other opioids or sedatives have they received in the last 24 hours?
- Does the order match the correct tablet strength (mg) and formulation (IR vs ER)?
- Are naloxone and airway support immediately available?
- If ventilation is declining, have I held oxycodone and activated escalation?
Oxycodone NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for oxycodone using a tabbed postoperative case (MAR, labs, vitals, nursing notes), then rotate priority action, respiratory cue recognition, deterioration trends, matrix urgency sorting, antagonist management, and antidote cloze—recognise cues → analyse → prioritise → act → evaluate outcomes tied to respiratory depression and immediate-release versus extended-release safety.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Oxycodone 10 mg PO q4h PRN moderate pain — 10 mg given at 1400 (immediate-release tablet)
- Lorazepam 0.5 mg PO q6h PRN anxiety — 0.5 mg at 1330
- Oxycodone 10 mg PO PRN due 1800; bedside cup holds 10 mg IR tablet and a separate OxyContin 20 mg ER tablet brought from home
- 1730: patient reports pain 8/10; no oxycodone documented since 1400 dose
- Admission BMP: creatinine 1.1 mg/dL; eGFR 78 mL/min/1.73 m2
- Pharmacy note: patient converted from IV hydromorphone yesterday—conservative oxycodone titration ordered
- ABG not drawn; SpO2 monitoring per post-op protocol
- 1415 (15 min post 10 mg PO): RR 16, SpO2 96% on room air, easily arousable
- 1700: RR 11, SpO2 93% on 2 L/min, drowsy but oriented
- 1730: RR 9, SpO2 90% on 2 L/min, difficult to arouse with verbal stimulus
- 72-year-old post hip fracture repair, day 1; history of COPD and home oxygen at night
- 1720: Patient drifting to sleep mid-sentence; roommate notes loud snoring
- 1730: Nurse preparing oxycodone for pain 8/10; patient asks whether the “long-acting” tablet can be crushed to swallow easier
- Naloxone available on unit per protocol
Answer key & rationale
Frequently asked questions
What is the greatest nursing safety risk with oxycodone?
Serious, life-threatening, or fatal respiratory depression may occur with oxycodone, especially during initiation or after a dose increase. Labeling directs close monitoring especially within the first 24 to 72 hours. Concomitant benzodiazepines or other CNS depressants increase fatal respiratory depression risk. Crushing extended-release tablets can release a potentially fatal dose.
What immediate-release adult dosing does oxycodone hydrochloride tablet labeling describe?
When oxycodone hydrochloride is the first opioid analgesic, reviewed labeling initiates treatment in a dosing range of 5 to 15 mg every 4 to 6 hours as needed for pain, at the lowest dose necessary to achieve adequate analgesia, with titration based on individual response. Extended-release products have separate prescribing information.
What antidote is used for oxycodone respiratory depression?
Opioid antagonists such as naloxone are specific antidotes to respiratory depression resulting from opioid overdose per reviewed prescribing information. Continue monitoring and repeat antagonist doses as directed because reversal duration may be shorter than oxycodone action. Contact local poison control or medical toxicology services per facility protocol.
When should a nurse hold oxycodone and contact the prescriber or pharmacist?
Hold for significant respiratory depression, acute or severe bronchial asthma in an unmonitored setting, gastrointestinal obstruction, MAOI use within 14 days, hypersensitivity, excessive sedation or apnea, wrong tablet strength or formulation (IR vs ER), or new CNS depressants without a safe concurrent plan.
Is oxycodone safe during breastfeeding?
Oxycodone is present in breast milk. Reviewed labeling states that doses less than 60 mg per day of immediate-release oxycodone are unlikely to result in clinically relevant exposures in breastfed infants, but infants should be monitored for sedation and respiratory depression. Discuss alternatives with the prescriber when concern exists.
References
-
DailyMed — Oxycodone Hydrochloride Tablets (KVK-Tech, Inc.), revised prescribing informationhttps://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa7ac2bf-d9ed-445d-b394-4d3fe39780ca
-
LactMed — Oxycodone (NIH/NLM drugs and lactation database)https://www.ncbi.nlm.nih.gov/books/NBK501256/
-
FDA — OxyContin (oxycodone hydrochloride) extended-release tablets prescribing informationhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022272s048lbl.pdf
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.